This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Jan;17(1):3.

doi: 10.1038/s41584-020-00547-1.

Febuxostat cardiovascular safety revisited

Affiliations

PMID: 33219346
DOI: 10.1038/s41584-020-00547-1

Comment

Febuxostat cardiovascular safety revisited

Sarah Onuora. Nat Rev Rheumatol. 2021 Jan.

. 2021 Jan;17(1):3.

doi: 10.1038/s41584-020-00547-1.

Author

Affiliation

¹ Nature Reviews Rheumatology, . nrrheum@nature.com.

PMID: 33219346
DOI: 10.1038/s41584-020-00547-1

No abstract available

PubMed Disclaimer

Comment on

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Clinical Trial.

References

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Medical
- MedlinePlus Health Information